JP2013519721A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519721A5
JP2013519721A5 JP2012553409A JP2012553409A JP2013519721A5 JP 2013519721 A5 JP2013519721 A5 JP 2013519721A5 JP 2012553409 A JP2012553409 A JP 2012553409A JP 2012553409 A JP2012553409 A JP 2012553409A JP 2013519721 A5 JP2013519721 A5 JP 2013519721A5
Authority
JP
Japan
Prior art keywords
mhc class
molecule
recombinant
cysteine residues
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012553409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519721A (ja
JP5537675B2 (ja
Filing date
Publication date
Priority claimed from GBGB1002730.8A external-priority patent/GB201002730D0/en
Application filed filed Critical
Publication of JP2013519721A publication Critical patent/JP2013519721A/ja
Publication of JP2013519721A5 publication Critical patent/JP2013519721A5/ja
Application granted granted Critical
Publication of JP5537675B2 publication Critical patent/JP5537675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012553409A 2010-02-18 2011-02-18 ジスルフィド結合により安定化された機能的可溶性mhcクラスiiヘテロ二量体 Active JP5537675B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30572810P 2010-02-18 2010-02-18
GBGB1002730.8A GB201002730D0 (en) 2010-02-18 2010-02-18 Product
GB1002730.8 2010-02-18
US61/305,728 2010-02-18
US31657610P 2010-03-23 2010-03-23
US61/316,576 2010-03-23
PCT/GB2011/050325 WO2011101681A2 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Publications (3)

Publication Number Publication Date
JP2013519721A JP2013519721A (ja) 2013-05-30
JP2013519721A5 true JP2013519721A5 (enExample) 2014-03-27
JP5537675B2 JP5537675B2 (ja) 2014-07-02

Family

ID=42113985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012553409A Active JP5537675B2 (ja) 2010-02-18 2011-02-18 ジスルフィド結合により安定化された機能的可溶性mhcクラスiiヘテロ二量体

Country Status (18)

Country Link
US (2) US8828379B2 (enExample)
EP (1) EP2536746B1 (enExample)
JP (1) JP5537675B2 (enExample)
KR (1) KR101647176B1 (enExample)
CN (1) CN102947330B (enExample)
AU (1) AU2011217027B2 (enExample)
CA (1) CA2789492C (enExample)
CY (1) CY1117697T1 (enExample)
DK (1) DK2536746T3 (enExample)
ES (1) ES2572388T3 (enExample)
GB (1) GB201002730D0 (enExample)
HR (1) HRP20160475T1 (enExample)
HU (1) HUE027952T2 (enExample)
PL (1) PL2536746T3 (enExample)
RS (1) RS54744B1 (enExample)
RU (1) RU2604813C2 (enExample)
SI (1) SI2536746T1 (enExample)
WO (1) WO2011101681A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP3901280B1 (en) 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
LT3167065T (lt) * 2014-07-09 2020-07-27 Lupin Limited Dviguba cistroninė bakterinė raiškos sistema
WO2017004252A1 (en) 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
DK3817757T3 (da) 2018-07-06 2026-03-09 Univ California Peptid-deficient mhc-klasse-i/chaperon-sammensætninger og fremgangsmåder
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
WO2020064915A1 (en) * 2018-09-28 2020-04-02 Danmarks Tekniske Universitet High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
EP4028412A2 (en) * 2019-09-13 2022-07-20 The Regents of The University of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
WO2021113297A1 (en) * 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021138688A1 (en) 2020-01-03 2021-07-08 The Regents Of The University Of California Systems and methods for identification of mhc-i peptide epitopes
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
DE102020109447A1 (de) 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
TW202321312A (zh) * 2021-09-08 2023-06-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含基於mhc或mhc樣蛋白的異源二聚體的二價雙特異性嵌合抗體
CN118813436A (zh) * 2023-07-24 2024-10-22 佳吾益(北京)科技有限公司 展示单mhc等位基因功能蛋白的工程化细胞
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DK0935607T3 (da) 1996-08-16 2004-12-06 Harvard College Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
AU741130B2 (en) * 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
NZ507886A (en) * 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
CA2638892A1 (en) * 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
WO2008017517A1 (en) * 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
CN101548240B (zh) * 2006-12-01 2014-09-17 卡尔蔡司Smt有限责任公司 具有用于减小像差的可替换、可操纵的校正布置的光学系统
EP2193199B1 (en) 2007-08-20 2013-11-06 Nextera AS Pvii phage display

Similar Documents

Publication Publication Date Title
RU2012138302A (ru) Функциональные растворимые гетеродимеры мнс ii класса со стабилизирующей дисульфидной связью
JP2019521643A5 (enExample)
JP2016532693A5 (enExample)
JP7682927B2 (ja) 特異的結合性分子
JP2010227116A5 (enExample)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2017512063A5 (enExample)
JP2013537416A5 (enExample)
JP2017501728A5 (enExample)
HRP20231382T1 (hr) Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba
JP2017509335A5 (enExample)
JP2014510518A5 (enExample)
JP2014505463A5 (enExample)
JP2013530929A5 (enExample)
JP2013538566A5 (enExample)
JP2018532372A5 (enExample)
IL309260B1 (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
JP2014530001A5 (enExample)
JP2024547218A5 (enExample)
TW202233694A (zh) 雙特異性抗體
JP2013511966A5 (enExample)
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
JP2022538922A (ja) ペプチド-mhc複合体
JP2015515969A5 (enExample)
JP2023532760A (ja) 特異的結合分子